Literature DB >> 21371436

Hepatitis C virus RNA replication in human stellate cells regulates gene expression of extracellular matrix-related molecules.

Noriyuki Watanabe1, Hideki Aizaki, Tomokazu Matsuura, Soichi Kojima, Takaji Wakita, Tetsuro Suzuki.   

Abstract

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, including chronic hepatitis, fibrosis, and cirrhosis. Fibrosis often develops in HCV-infected livers and ultimately leads to cirrhosis and carcinoma. During fibrosis, hepatic stellate cells (HSC) play important roles in the control of extracellular matrix synthesis and degradation in fibrotic livers. In this study, we established a subgenomic replicon (SGR) cell line with human hepatic stellate cells to investigate the effect of HCV RNA replication on HSC. Isolated SGR clones contained HCV RNA copy numbers ranging from 10(4) to 10(7) per μg total RNA, and long-term culture of low-copy number SGR clones resulted in markedly increased HCV RNA copy numbers. Furthermore, HCV RNA replication affected gene expression of extracellular matrix-related molecules in both hepatic stellate cells and hepatic cells, suggesting that HCV RNA replication and/or HCV proteins directly contribute to liver fibrosis. The HCV RNA-replicating hepatic stellate cell line isolated in this study will be useful for investigating hepatic stellate cell functions and HCV replication machinery.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371436     DOI: 10.1016/j.bbrc.2011.02.125

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients.

Authors:  Angela L Rasmussen; Nicolas Tchitchek; Nathan J Susnow; Alexei L Krasnoselsky; Deborah L Diamond; Matthew M Yeh; Sean C Proll; Marcus J Korth; Kathie-Anne Walters; Sharon Lederer; Anne M Larson; Robert L Carithers; Arndt Benecke; Michael G Katze
Journal:  Hepatology       Date:  2012-06-05       Impact factor: 17.425

2.  Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus.

Authors:  Takasuke Fukuhara; Hiroto Kambara; Mai Shiokawa; Chikako Ono; Hiroshi Katoh; Eiji Morita; Daisuke Okuzaki; Yoshihiko Maehara; Kazuhiko Koike; Yoshiharu Matsuura
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Biological significance of HCV in various kinds of lymphoid cells.

Authors:  Yasuteru Kondo; Yoshiyuki Ueno; Tooru Shimosegawa
Journal:  Int J Microbiol       Date:  2012-02-22

4.  HCV derived from sera of HCV-infected patients induces pro-fibrotic effects in human primary fibroblasts by activating GLI2.

Authors:  M Granato; C Zompetta; E Vescarelli; C Rizzello; A Cardi; S Valia; G Antonelli; C Marchese; M R Torrisi; A Faggioni; M Cirone
Journal:  Sci Rep       Date:  2016-08-01       Impact factor: 4.379

5.  Infection of Human Liver Myofibroblasts by Hepatitis C Virus: A Direct Mechanism of Liver Fibrosis in Hepatitis C.

Authors:  Lynda Aoudjehane; Grégoire Bisch; Olivier Scatton; Christelle Granier; Jesintha Gaston; Chantal Housset; Philippe Roingeard; François-Loïc Cosset; Fabiano Perdigao; Pierre Balladur; Takaji Wakita; Yvon Calmus; Filomena Conti
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

6.  The transcriptomic response of rat hepatic stellate cells to endotoxin: implications for hepatic inflammation and immune regulation.

Authors:  Stephen A K Harvey; Anil Dangi; Ashish Tandon; Chandrashekhar R Gandhi
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

7.  Inhibition of tyrosine kinase receptor Tie2 reverts HCV-induced hepatic stellate cell activation.

Authors:  Samuel Martín-Vílchez; Yolanda Rodríguez-Muñoz; Rosario López-Rodríguez; María Jesús Borque-Iñurrita; Francisca Molina-Jiménez; Luisa García-Buey; Ricardo Moreno-Otero; Paloma Sanz-Cameno
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.